Find Clinical Trial

Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A randomised, double-blind, multicentre, placebo controlled, phase II/III dose-finding study with a PK/PD characterisation and a 1 year efficacy/safety evaluation.


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

Active substance/
Medical device

S016257, IVABRADINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS016257
Protocol CodeCL2-16257-090
EudraCT Code2011-001292-39
ISRCTN CodeISRCTN60567801


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility